HomeCompareASCLF vs PFE

ASCLF vs PFE: Dividend Comparison 2026

ASCLF yields 110.50% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ASCLF wins by $5.88M in total portfolio value
10 years
ASCLF
ASCLF
● Live price
110.50%
Share price
$1.81
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.93M
Annual income
$2,132,830.87
Full ASCLF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — ASCLF vs PFE

📍 ASCLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodASCLFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ASCLF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ASCLF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ASCLF
Annual income on $10K today (after 15% tax)
$9,392.27/yr
After 10yr DRIP, annual income (after tax)
$1,812,906.24/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, ASCLF beats the other by $1,790,586.34/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ASCLF + PFE for your $10,000?

ASCLF: 50%PFE: 50%
100% PFE50/50100% ASCLF
Portfolio after 10yr
$2.99M
Annual income
$1,079,544.80/yr
Blended yield
36.11%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

ASCLF
No analyst data
Altman Z
61.0
Piotroski
1/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ASCLF buys
0
PFE buys
0
No recent congressional trades found for ASCLF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricASCLFPFE
Forward yield110.50%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$5.93M$49.6K
Annual income after 10y$2,132,830.87$26,258.71
Total dividends collected$5.35M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ASCLF vs PFE ($10,000, DRIP)

YearASCLF PortfolioASCLF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$21,750$11,049.72$9,153$693.39+$12.6KASCLF
2$45,733$22,460.60$8,593$849.25+$37.1KASCLF
3$93,072$44,137.91$8,336$1,066.78+$84.7KASCLF
4$183,537$83,949.70$8,437$1,384.80+$175.1KASCLF
5$351,102$154,717.47$9,013$1,875.40+$342.1KASCLF
6$652,287$276,608.54$10,306$2,680.72+$642.0KASCLF
7$1,178,220$480,272.57$12,820$4,101.38+$1.17MASCLF
8$2,071,454$810,758.34$17,673$6,826.70+$2.05MASCLF
9$3,548,616$1,332,160.25$27,543$12,591.86+$3.52MASCLF
10$5,929,850$2,132,830.87$49,560$26,258.71+$5.88MASCLF

ASCLF vs PFE: Complete Analysis 2026

ASCLFStock

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB) and human immunodeficiency virus functional cure; ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.

Full ASCLF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this ASCLF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ASCLF vs SCHDASCLF vs JEPIASCLF vs OASCLF vs KOASCLF vs MAINASCLF vs JNJASCLF vs MRKASCLF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.